World Class Manufacturing Units
Vyas Lifesciences operates multiple world-class manufacturing units strategically designed for scalable, high-quality production of APIs and intermediates, with each facility fully equipped to meet global regulatory standards.
Unit-1
Spanning 4 acres, houses 35 reactors with a total installed capacity of 103 KL. This facility is approved by WHO-GMP, USFDA, EDQM, PMDA, MFDS, ANVISA, NMPA China, and COFEPRIS, ensuring compliance with the highest international quality standards.
Unit-2
Our largest operational facility covering 10.6 acres, comprises 129 reactors with a capacity of 408 KL. Like Unit-1, it holds approvals from WHO-GMP, USFDA, EDQM, PMDA, MFDS, ANVISA, NMPA China, and COFEPRIS, reflecting our commitment to consistent quality and regulatory excellence.
Unit-3
Spread over 9 acres, includes 69 reactors with 246 KL of capacity and is approved by WHO-GMP, USFDA, EDQM, PMDA, MFDS, ANVISA, and COFEPRIS, supporting both clinical and commercial production needs.
Unit-5
Our most expansive facility, spans 26 acres with 120 reactors and a capacity of 764 KL. Designed for flexible, large-scale manufacturing, it is WHO-GMP certified, with USFDA inspection anticipated in 2026, marking the next step in expanding our global regulatory footprint.
Together, these facilities position Vyas Lifesciences as a trusted CDMO partner capable of delivering high-quality, compliant, and scalable solutions for pharmaceutical and specialty chemical innovators worldwide.
Manufacturing Capabilities
Unit-1
4 Acres
35 Reactors
103 KL
- WHO-GMP, USFDA
- EDQM, PMDA
- MFDS, ANVISA
- NMPA China
- COFEPRIS
Unit-2
10.6 Acres
129 Reactors
408 KL
- WHO-GMP, USFDA
- EDQM, PMDA
- MFDS, ANVISA
- NMPA China
- COFEPRIS
Unit-3
9 Acres
69 Reactors
246 KL
- WHO-GMP, USFDA
- EDQM, PMDA
- MFDS, ANVISA
- COFEPRIS
Unit-5
26 Acres
120 Reactors
764 KL
- WHO-GMP
- USFDA Inspection
expected in 2026
